The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study.
Raja Padidela, Ola Nilsson, Outi Makitie...
https://pubmed.ncbi.nlm.nih.gov/32605590/Actively Recruiting
Led by Kyowa Kirin Pharmaceutical Development Ltd · Updated on 2026-07-09
1489
Participants Needed
118
Research Sites
21 weeks
Total Duration
Researchers are conducting an international, multicenter, prospective observational registry to study patients with X-Linked Hypophosphatemia XLH. This registry aims to collect detailed data on the natural history, treatment patterns, progression, and long-term outcomes of XLH in both adults and children. The study includes patients regardless of whether they are currently receiving treatment for XLH. Participants will be enrolled in a non-interventional setting without any additional treatments or procedures beyond their standard clinical care. Data will be collected retrospectively and prospectively using a web-based system. Physicians will update patient information during routine visits, with reminders to update data approximately every 12 months. Some sites may also participate in a post-authorization safety study PASS to monitor treatment-related adverse events. Participants will provide informed consent or assent according to age and national guidelines. The study team will collect baseline and ongoing clinical information, including treatment details and adverse events, over a period extending to 10 years. No fixed follow-up schedule is required, but data updates align with patients usual healthcare visits. Researchers will review adverse events related to treatment as a primary outcome measure throughout the study period.
CONDITIONS
Registry for Patients With X-Linked Hypophosphatemia
C
Clinical Trial Cordinator
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Kyowa Kirin Pharmaceutical Development Ltd
Lead Sponsor
IQVIA Pty Ltd
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 10 years
Participants continue with their usual healthcare visits where physicians collect and update data about their XLH condition and treatments. Data entry occurs during routine visits with reminders approximately every 12 months.
Data updates at routine healthcare visits, approximately every 12 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Raja Padidela, Ola Nilsson, Outi Makitie...
https://pubmed.ncbi.nlm.nih.gov/32605590/Thomas O Carpenter, Seiji Fukumoto, Dieter Haffner...
https://pubmed.ncbi.nlm.nih.gov/40962182/Gema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot...
https://pubmed.ncbi.nlm.nih.gov/37752558/Maria Luisa Brandi, Gema Ariceta, Signe Sparre Beck-Nielsen...
https://pubmed.ncbi.nlm.nih.gov/36082134/Karine Briot, Sandrine Lemoine, Bernard Cortet...
https://pubmed.ncbi.nlm.nih.gov/42038817/Agnès Linglart, Cyril Amouroux, Iva Gueorguieva...
https://pubmed.ncbi.nlm.nih.gov/41030383/Kyowa Kirin Pharmaceutical Development Ltd
Lead Sponsor
IQVIA Pty Ltd
Collaborating Sponsor